Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is showing promising results in early clinical assessments . Recent research suggests https://gorillasocialwork.com/story26783743/retatrutide-emerging-research-and-projected-therapeutic-uses